KLRG1 and neoplasm: Primary tumor growth was inhibited by anti-KLRG1 + anti-PD-1 antibody greater than anti-KLRG1 antibody or anti-PD-1 antibody or control antibody alone (MC38: day 16 tumor volume 582 vs. 1259 vs. 1279 vs. 1461 mm3, respectively, Figure 2C; B16F10: day 21 tumor volume 544 vs 1799 vs 1464 vs 1687 mm3, respectively, Figure 2E).